Renal Transplant Immunosuppression in Patients With Hemolytic Uremic Syndrome: Four Case Reports.

Autor: Galindo P; Servicio de Nefrología, H.U. Virgen de las Nieves, Granada, Spain. Electronic address: pglaura@telefonica.net., Ramirez M; Centro de Diálisis, Nevada, Granada, Spain., Pérez Marfil A; Servicio de Nefrología, H.U. Virgen de las Nieves, Granada, Spain., Espigares MJ; Centro de Diálisis, Nevada, Granada, Spain., Osoria JM; Centro de Diálisis, Nevada, Granada, Spain., Leiva R; Centro de Diálisis, Nevada, Granada, Spain., Ruiz Fuentes MC; Centro de Diálisis, Nevada, Granada, Spain., De Gracia C; Centro de Diálisis, Nevada, Granada, Spain., Osuna A; Centro de Diálisis, Nevada, Granada, Spain.
Jazyk: angličtina
Zdroj: Transplantation proceedings [Transplant Proc] 2018 Mar; Vol. 50 (2), pp. 572-574.
DOI: 10.1016/j.transproceed.2017.11.056
Abstrakt: A high rate of recurrence has been described in atypical hemolytic uremic syndrome renal transplant recipients, favored by certain immunosuppressant drugs that can induce complement activation. We present four case series in which three patients were diagnosed pretransplantation and a fourth who had onset in the very early post-transplantation period. The patients received different immunosuppression schedules, and all had improvement after more than 2-years. We suggest the need to stratify the risk of atypical hemolytic uremic syndrome recurrence using genetic studies and the available drugs as the main factors that allow graft survival improvement today.
(Copyright © 2018 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: